PBM changes unlikely to join spending bill as shutdown loomsnews2024-12-20T20:17:15+00:00December 20th, 2024|Endpoints News|
Accelerated approval brings Pfizer’s BRAF inhibitor to first-line patientsnews2024-12-20T20:05:59+00:00December 20th, 2024|Endpoints News|
FDA’s Califf predicts Ramaswamy-RFK battle over agencynews2024-12-20T19:20:44+00:00December 20th, 2024|Endpoints News|
Rhythm receives expanded approval for genetic obesity drugnews2024-12-20T19:17:04+00:00December 20th, 2024|Endpoints News|
FDA approves Humacyte’s lab-grown blood vesselsnews2024-12-20T18:53:56+00:00December 20th, 2024|Endpoints News|
GSK’s Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survivalnews2024-12-20T16:37:07+00:00December 20th, 2024|Endpoints News|
Sofinnova outlines $550M fund after IPOs and M&A dealsnews2024-12-20T16:08:52+00:00December 20th, 2024|Endpoints News|
Applied Therapeutics CEO steps down after rare disease drug rejectionnews2024-12-20T15:44:47+00:00December 20th, 2024|Endpoints News|
Idorsia’s Tryvio deal delay; Galectin’s liver drug disappointsnews2024-12-20T15:16:16+00:00December 20th, 2024|Endpoints News|
Commure’s latest acquisition sends follow-up texts to patientsnews2024-12-20T13:00:23+00:00December 20th, 2024|Endpoints News|
